Download Report

THE DRIVE TO DISCOVER.
THE EXPERIENCE TO DELIVER.
October 2014
www.incyte.com
OVERVIEW
Ÿ
A fully-integrated biopharmaceutical company focused on the discovery, development and
commercialization of proprietary small molecule drugs, primarily for oncology
Ÿ
A world class team of highly experienced scientists and pharmaceutical professionals collaborating across
all disciplines, backed by a solid financial position
Ÿ
An approach that is marked by rigorous science, effective teamwork, disciplined program execution and an
unwavering commitment to patients
Ÿ
An FDA-approved product, Jakafi® (ruxolitinib) for the treatment of patients with intermediate or high-risk
myelofibrosis (MF), and a rich portfolio of novel compounds under development
Ÿ
An experienced U.S. commercial organization, plus strategic collaborations with top-tier pharmaceutical
companies to deliver its novel therapeutics worldwide
“The field of oncology is evolving at an unprecedented pace, and
Incyte has a central position in the ongoing transformation in how
cancer patients are treated.”
Hervé Hoppenot
Incyte President and Chief Executive Officer
ADVANCED PIPELINE
Incyte has an broad pipeline of product candidates, primarily focused on oncology.
Compound
Jakaﬁ® (ruxolitinib)
Target
JAK1 / JAK2
Indication
Proof of Concept Trials
Pivotal Trials
Myeloﬁbrosis a
Polycythemia vera a
Pancreatic cancer b
Advanced malignancies b
Non-small cell lung cancer b
Breast cancer b
Colorectal cancer b
INCB39110
JAK1
Advanced malignancies
INCB24360
IDO1
Metastatic melanoma
Non-small cell lung cancer
Incyte Corporation
Quick Facts
Non-small cell lung cancer c
Non-small cell lung cancer * d
Established in 1991
Approximately 600 employees
IPO in 1993
NASDAQ symbol: INCY
Multiple cancers * e
Multiple cancers * f
INCB40093
PI3Kδ
B-lymphoid malignancies
INCB40093+INCB39110 PI3Kδ + JAK1
B-lymphoid malignancies
INC280 g
Hepatocellular carcinoma
c-MET
Non-small cell lung cancer
Solid tumors
Baricitinib h
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
www.incyte.com
855.4.INCYTE (855.466.2983)
JAK1 / JAK2
Rheumatoid arthritis
Psoriasis
Diabetic nephropathy
a Incyte: U.S. rights; Novartis: ex-U.S. rights b Incyte: U.S. rights c In combination with Merck’s MK-3475 d In combination with Genentech’s MPDL3280A
e In combination with MedImmune’s MEDI4736 f In combination with Bristol-Myers Squibb’s nivolumab g Novartis: worldwide rights h Lilly: worldwide rights
* Trial not yet initiated
Marketed
A PATHWAY TO GROWTH
®
Jakafi (ruxolitinib) is approved in the United States for the treatment of intermediate or high-risk myelofibrosis (MF),
a myeloproliferative neoplasm and a type of rare blood cancer. Jakafi is an oral treatment that inhibits the Janus
kinases JAK1 and JAK2, resulting in the down-modulation of overactive JAK signaling. Over-active or dysregulated
JAK1 and JAK2 has been linked to the enlarged spleens and debilitating symptoms seen in the majority of patients
with MF.
Ruxolitinib recently met the primary endpoint in the pivotal Phase III RESPONSE study of patients with polycythemia
vera (PV), a second myeloproliferative neoplasm and for which ruxolitinib use is investigational and not approved.
Ruxolitinib is also in clinical development for the treatment of patients with other types of cancer, including
pancreatic, lung, breast and colorectal cancers.
“During clinical trials, Jakafi provided significant reductions
in spleen size and significant improvements in symptoms in
patients with myelofibrosis.”
Srdan Verstovsek, M.D., Ph.D.
MD Anderson Cancer Center, Houston, Texas
INDICATIONS AND USAGE
Jakafi is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis,
post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.
IMPORTANT SAFETY INFORMATION
Jakafi can cause serious side effects including:
Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop
bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood
counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop
your treatment based on the results of your blood tests. Tell your healthcare provider right away if you experience unusual bleeding,
bruising, fatigue, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection while taking Jakafi. Tell your healthcare provider if you develop
symptoms such as chills, nausea, vomiting, aches, weakness, fever, or painful skin rash or blisters.
The most common side effects of Jakafi include dizziness and headache.
These are not all the possible side effects of Jakafi. Ask your healthcare provider or pharmacist for more information. Tell your
healthcare provider about any side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and
all your medical conditions, including if you have an infection, have or had liver or kidney problems, are on dialysis, or have any
other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change or stop taking Jakafi without first
talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.
Contact
Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.
Please see the Full Prescribing Information available at www.jakafi.com, which includes a more complete discussion of
the risks associated with Jakafi.
www.incyte.com
Incyte and Jakafi are registered trademarks of Incyte Corporation.
© Copyright 2010 - 2014 Incyte Corporation. All rights reserved.
|
www.jakafi.com
REV 10 13 2014
Pamela M. Murphy
VP, Investor Relations and
Corporate Communications
855.4.INCYTE (855.466.2983)
[email protected]